scholarly article | Q13442814 |
review article | Q7318358 |
P50 | author | Anna Kula-Pacurar | Q95605915 |
Stéphane De Wit | Q47006685 | ||
Gilles Darcis | Q47143122 | ||
P2093 | author name string | Alessandro Marcello | |
Olivier Rohr | |||
Carine Van Lint | |||
Patrick W G Mallon | |||
Roxane Verdikt | |||
Amina Ait-Ammar | |||
Virginie Gautier | |||
P2860 | cites work | Genetic Evidence That Naive T Cells Can Contribute Significantly to the Human Immunodeficiency Virus Intact Reservoir: Time to Re-evaluate Their Role | Q91819323 |
Strategies to eradicate HIV from infected patients: elimination of latent provirus reservoirs | Q92300043 | ||
Interferon-inducible TRIM22 contributes to maintenance of HIV-1 proviral latency in T cell lines | Q92344530 | ||
A CRISPR/Cas9 screen identifies the histone demethylase MINA53 as a novel HIV-1 latency-promoting gene (LPG) | Q92532794 | ||
Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab | Q92668726 | ||
HIV Diversity and Genetic Compartmentalization in Blood and Testes during Suppressive Antiretroviral Therapy | Q92689699 | ||
Latency reversal agents affect differently the latent reservoir present in distinct CD4+ T subpopulations | Q92697820 | ||
HIV Rebound Is Predominantly Fueled by Genetically Identical Viral Expansions from Diverse Reservoirs | Q93020860 | ||
HIV Silencing and Inducibility Are Heterogeneous and Are Affected by Factors Intrinsic to the Virus | Q93023822 | ||
CD32 expressing doublets in HIV-infected gut-associated lymphoid tissue are associated with a T follicular helper cell phenotype | Q93025028 | ||
A novel bromodomain inhibitor, CPI-203, serves as an HIV-1 latency-reversing agent by activating positive transcription elongation factor b | Q93129465 | ||
Recruitment of chromatin-modifying enzymes by CTIP2 promotes HIV-1 transcriptional silencing | Q24294385 | ||
Regulation of HIV-1 gene expression by histone acetylation and factor recruitment at the LTR promoter | Q24634457 | ||
Recruitment of Tat to heterochromatin protein HP1 via interaction with CTIP2 inhibits human immunodeficiency virus type 1 replication in microglial cells | Q24679559 | ||
Redefining the viral reservoirs that prevent HIV-1 eradication | Q26827255 | ||
Histone deacetylase inhibitors impair the elimination of HIV-infected cells by cytotoxic T-lymphocytes | Q27324527 | ||
Retroviruses use CD169-mediated trans-infection of permissive lymphocytes to establish infection | Q27331323 | ||
Are T cells the only HIV-1 reservoir? | Q28078850 | ||
7SK small nuclear RNA binds to and inhibits the activity of CDK9/cyclin T complexes | Q28116607 | ||
NELF, a multisubunit complex containing RD, cooperates with DSIF to repress RNA polymerase II elongation | Q28141291 | ||
The 7SK small nuclear RNA inhibits the CDK9/cyclin T1 kinase to control transcription | Q28206012 | ||
A human memory T cell subset with stem cell-like properties | Q28248395 | ||
A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA | Q28263974 | ||
Epigenetic regulation of HIV-1 latency by cytosine methylation | Q28475636 | ||
Deep molecular characterization of HIV-1 dynamics under suppressive HAART | Q28477677 | ||
An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients | Q28538015 | ||
Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy | Q28544949 | ||
Synergistic Reactivation of Latent HIV Expression by Ingenol-3-Angelate, PEP005, Targeted NF-kB Signaling in Combination with JQ1 Induced p-TEFb Activation | Q28546901 | ||
An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression | Q28546918 | ||
HIV-1 structural gene expression requires the binding of multiple Rev monomers to the viral RRE: implications for HIV-1 latency | Q28646762 | ||
Analysis of HIV quasispecies suggests compartmentalization in the liver | Q42266226 | ||
In Vivo Suppression of HIV Rebound by Didehydro-Cortistatin A, a "Block-and-Lock" Strategy for HIV-1 Treatment. | Q42381408 | ||
CBF-1 promotes transcriptional silencing during the establishment of HIV-1 latency | Q42573954 | ||
c-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter | Q42638819 | ||
Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART). | Q42691966 | ||
Differential expression of CD45RO (UCHL1) and its functional relevance in two subpopulations of circulating TCR-gamma/delta+ lymphocytes | Q42937731 | ||
Orientation-dependent regulation of integrated HIV-1 expression by host gene transcriptional readthrough. | Q43226911 | ||
Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. | Q43792135 | ||
Both CD31(+) and CD31⁻ naive CD4(+) T cells are persistent HIV type 1-infected reservoirs in individuals receiving antiretroviral therapy | Q43941310 | ||
Comparison of HIV-1 pol and env sequences of blood, CSF, brain and spleen isolates collected ante-mortem and post-mortem | Q44740845 | ||
Negative regulation of HIV-1 transcription by a heterodimeric NF-κB1/p50 and C-terminally truncated STAT5 complex | Q44807679 | ||
Plasma and cerebrospinal fluid pharmacokinetics of depsipeptide (FR901228) in nonhuman primates | Q44813168 | ||
HIV-1 pre-mRNA commitment to Rev mediated export through PSF and Matrin 3. | Q45372623 | ||
Male genital tract compartmentalization of human immunodeficiency virus type 1 (HIV). | Q45395687 | ||
Genetic differences between human immunodeficiency virus type 1 subpopulations in faeces and serum | Q45757845 | ||
Identification of Genetically Intact HIV-1 Proviruses in Specific CD4+ T Cells from Effectively Treated Participants. | Q46281767 | ||
The Spleen Is an HIV-1 Sanctuary During Combined Antiretroviral Therapy | Q46584933 | ||
Unique monocyte subset in patients with AIDS dementia | Q46631395 | ||
BET inhibitors RVX-208 and PFI-1 reactivate HIV-1 from latency | Q47120827 | ||
Curaxin CBL0100 Blocks HIV-1 Replication and Reactivation through Inhibition of Viral Transcriptional Elongation | Q47201695 | ||
Integrin α4β7 expression on peripheral blood CD4+ T cells predicts HIV acquisition and disease progression outcomes. | Q47549153 | ||
Higher sequence diversity in the vaginal tract than in blood at early HIV-1 infection. | Q47551736 | ||
PD-1 blockade in HIV-infected patients with lung cancer: a new challenge or already a strategy? | Q47551808 | ||
A new quinoline BRD4 inhibitor targets a distinct latent HIV-1 reservoir for re-activation from other 'shock' drugs | Q47552249 | ||
Getting the "Kill" into "Shock and Kill": Strategies to Eliminate Latent HIV. | Q47555333 | ||
Chidamide, a histone deacetylase inhibitor-based anticancer drug, effectively reactivates latent HIV-1 provirus. | Q47583584 | ||
CTLA-4+PD-1- Memory CD4+ T Cells Critically Contribute to Viral Persistence in Antiretroviral Therapy-Suppressed, SIV-Infected Rhesus Macaques | Q47608280 | ||
HIV-1 infection of monocytes is directly related to the success of HAART. | Q48078114 | ||
Blood CXCR3+ CD4 T Cells Are Enriched in Inducible Replication Competent HIV in Aviremic Antiretroviral Therapy-Treated Individuals | Q49829305 | ||
HIV latency is reversed by ACSS2-driven histone crotonylation | Q49851068 | ||
Drastic decrease of the HIV reservoir in a patient treated with nivolumab for lung cancer | Q50066861 | ||
Monocytes harbour replication-competent, non-latent HIV-1 in patients on highly active antiretroviral therapy. | Q52021616 | ||
The KAT5-Acetyl-Histone4-Brd4 axis silences HIV-1 transcription and promotes viral latency. | Q52312695 | ||
HIV latency in isolated patient CD4+ T cells may be due to blocks in HIV transcriptional elongation, completion, and splicing. | Q52680785 | ||
BI-2536 and BI-6727, dual Polo-like kinase/bromodomain inhibitors, effectively reactivate latent HIV-1. | Q52687695 | ||
Maraviroc is associated with latent HIV-1 reactivation through NF-κB activation in resting CD4+ T cells from HIV-Infected Individuals on Suppressive Antiretroviral Therapy. | Q52695029 | ||
Increased HIV-1 transcriptional activity and infectious burden in peripheral blood and gut-associated CD4+ T cells expressing CD30. | Q52731001 | ||
Novel Latency Reversal Agents for HIV-1 Cure. | Q52816327 | ||
CTL fail to accumulate at sites of HIV-1 replication in lymphoid tissue. | Q53551795 | ||
CD32 is expressed on cells with transcriptionally active HIV but does not enrich for HIV DNA in resting T cells. | Q53822439 | ||
Detection of infectious HIV in circulating monocytes from patients on prolonged highly active antiretroviral therapy. | Q54057499 | ||
CD32-Expressing CD4 T Cells Are Phenotypically Diverse and Can Contain Proviral HIV DNA. | Q54204987 | ||
Targeting the Latent Reservoir for HIV-1. | Q54210140 | ||
Seminal Simian Immunodeficiency Virus in Chronically Infected Cynomolgus Macaques Is Dominated by Virus Originating from Multiple Genital Organs. | Q54222581 | ||
Distinct chromatin functional states correlate with HIV latency reactivation in infected primary CD4+ T Cells. | Q54224088 | ||
Single-Cell RNA-Seq Reveals Transcriptional Heterogeneity in Latent and Reactivated HIV-Infected Cells. | Q54228206 | ||
Reduction in terminally differentiated T cells in virologically controlled HIV-infected aging patients on long-term antiretroviral therapy. | Q55281020 | ||
Diverse Impacts of HIV Latency-Reversing Agents on CD8+ T-Cell Function: Implications for HIV Cure. | Q55455666 | ||
The RNA surveillance proteins UPF1, UPF2 and SMG6 affect HIV-1 reactivation at a post-transcriptional level. | Q55514032 | ||
HIV-1 DNA load analysis in peripheral blood lymphocytes and monocytes from naïve and HAART-treated individuals | Q56993481 | ||
Single-Cell Analysis of Quiescent HIV Infection Reveals Host Transcriptional Profiles that Regulate Proviral Latency | Q57044843 | ||
Inconsistent HIV reservoir dynamics and immune responses following anti-PD-1 therapy in cancer patients with HIV infection | Q57053202 | ||
Combination of a Latency-Reversing Agent With a Smac Mimetic Minimizes Secondary HIV-1 Infection | Q57072848 | ||
Greater diversity of HIV DNA variants in the rectum compared to variants in the blood in patients without HAART | Q57095890 | ||
Histone deacetylase inhibitor chidamide promotes reactivation of latent human immunodeficiency virus by introducing histone acetylation | Q57164880 | ||
Discordance Between Cerebral Spinal Fluid and Plasma HIV Replication in Patients with Neurological Symptoms Who Are Receiving Suppressive Antiretroviral Therapy | Q57176735 | ||
Genetic characterization of the HIV-1 reservoir after Vacc-4x and romidepsin therapy in HIV-1-infected individuals | Q57201701 | ||
Exposure to Prostratin but Not Bryostatin-1 Improves Natural Killer Cell Functions Including Killing of CD4 T Cells Harboring Reactivated Human Immunodeficiency Virus | Q57565007 | ||
Programmed cell death-1 contributes to the establishment and maintenance of HIV-1 latency | Q58003757 | ||
Metagenomic sequencing of HIV-1 in the blood and female genital tract reveals little quasispecies diversity during acute infection | Q58089557 | ||
Sex-Based Differences in HIV-1 Reservoir Activity and Residual Immune Activation | Q58104425 | ||
BIRC2/cIAP1 Is a Negative Regulator of HIV-1 Transcription and Can Be Targeted by Smac Mimetics to Promote Reversal of Viral Latency. | Q36198250 | ||
Convergence of TCR and cytokine signaling leads to FOXO3a phosphorylation and drives the survival of CD4+ central memory T cells | Q36228932 | ||
Early Antiretroviral Therapy Is Associated with Lower HIV DNA Molecular Diversity and Lower Inflammation in Cerebrospinal Fluid but Does Not Prevent the Establishment of Compartmentalized HIV DNA Populations | Q36238501 | ||
Immunological biomarkers predict HIV-1 viral rebound after treatment interruption | Q36250043 | ||
LEDGF/p75 interacts with mRNA splicing factors and targets HIV-1 integration to highly spliced genes | Q36286785 | ||
Bromodomain and extra-terminal (BET) bromodomain inhibition activate transcription via transient release of positive transcription elongation factor b (P-TEFb) from 7SK small nuclear ribonucleoprotein | Q36332978 | ||
Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation | Q36409885 | ||
In Vitro Reactivation of Replication-Competent and Infectious HIV-1 by Histone Deacetylase Inhibitors | Q36523946 | ||
Sequential treatment with 5-aza-2'-deoxycytidine and deacetylase inhibitors reactivates HIV-1. | Q36525896 | ||
Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production | Q36547664 | ||
HIV latency: experimental systems and molecular models. | Q36585019 | ||
In vivo, in vitro, and in silico analysis of methylation of the HIV-1 provirus. | Q36592182 | ||
Development of 5' LTR DNA methylation of latent HIV-1 provirus in cell line models and in long-term-infected individuals | Q36596027 | ||
Germinal Center T Follicular Helper Cells Are Highly Permissive to HIV-1 and Alter Their Phenotype during Virus Replication | Q36655850 | ||
Peripheral T Follicular Helper Cells Are the Major HIV Reservoir within Central Memory CD4 T Cells in Peripheral Blood from Chronically HIV-Infected Individuals on Combination Antiretroviral Therapy. | Q36736667 | ||
HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression | Q36781531 | ||
The BET inhibitor OTX015 reactivates latent HIV-1 through P-TEFb | Q36790027 | ||
CD133+ hematopoietic progenitor cells harbor HIV genomes in a subset of optimally treated people with long-term viral suppression | Q36846285 | ||
HIV-1 transcription and latency: an update | Q36976156 | ||
Long noncoding RNA NRON contributes to HIV-1 latency by specifically inducing tat protein degradation | Q37010047 | ||
The Effect of Latency Reversal Agents on Primary CD8+ T Cells: Implications for Shock and Kill Strategies for Human Immunodeficiency Virus Eradication | Q37034469 | ||
LEDGIN-mediated Inhibition of Integrase-LEDGF/p75 Interaction Reduces Reactivation of Residual Latent HIV | Q37035177 | ||
Reactivation of HIV latency by a newly modified Ingenol derivative via protein kinase Cδ-NF-κB signaling | Q37041173 | ||
CTIP2 is a negative regulator of P-TEFb | Q37068686 | ||
Defining HIV and SIV Reservoirs in Lymphoid Tissues. | Q37090999 | ||
High levels of CD2 expression identify HIV-1 latently infected resting memory CD4+ T cells in virally suppressed subjects. | Q37123276 | ||
The differential short- and long-term effects of HIV-1 latency-reversing agents on T cell function | Q37144949 | ||
HIV DNA and cognition in a Thai longitudinal HAART initiation cohort: the SEARCH 001 Cohort Study | Q37180359 | ||
The distribution of HIV DNA and RNA in cell subsets differs in gut and blood of HIV-positive patients on ART: implications for viral persistence | Q37187497 | ||
Defective proviruses rapidly accumulate during acute HIV-1 infection | Q37239064 | ||
Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors | Q37257484 | ||
Broad activation of latent HIV-1 in vivo | Q37260309 | ||
Reactivation of latent HIV-1 in central memory CD4⁺ T cells through TLR-1/2 stimulation | Q37305160 | ||
Compartmentalized HIV rebound in the central nervous system after interruption of antiretroviral therapy | Q37354047 | ||
Directly infected resting CD4+T cells can produce HIV Gag without spreading infection in a model of HIV latency | Q28728736 | ||
HIV-1 integration in the human genome favors active genes and local hotspots | Q29618457 | ||
HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation | Q29619611 | ||
Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection | Q29619738 | ||
A Subset of Latency-Reversing Agents Expose HIV-Infected Resting CD4+ T-Cells to Recognition by Cytotoxic T-Lymphocytes. | Q30385378 | ||
Peripheral Vγ9Vδ2 T Cells Are a Novel Reservoir of Latent HIV Infection | Q30400191 | ||
HIV-1 Recruits UPF1 but Excludes UPF2 to Promote Nucleocytoplasmic Export of the Genomic RNA. | Q30488459 | ||
Romidepsin-induced HIV-1 viremia during effective ART contains identical viral sequences with few deleterious mutations | Q30490742 | ||
Designed, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitro | Q30558754 | ||
HMBA releases P-TEFb from HEXIM1 and 7SK snRNA via PI3K/Akt and activates HIV transcription | Q30835037 | ||
Stochastic gene expression in a lentiviral positive-feedback loop: HIV-1 Tat fluctuations drive phenotypic diversity | Q33220546 | ||
Nuclear retention of multiply spliced HIV-1 RNA in resting CD4+ T cells | Q33250088 | ||
HIV-1 TAR element is processed by Dicer to yield a viral micro-RNA involved in chromatin remodeling of the viral LTR | Q33292464 | ||
Resting regulatory CD4 T cells: a site of HIV persistence in patients on long-term effective antiretroviral therapy | Q33373073 | ||
Control of stochastic gene expression by host factors at the HIV promoter | Q33398516 | ||
miR-198 inhibits HIV-1 gene expression and replication in monocytes and its mechanism of action appears to involve repression of cyclin T1 | Q33400321 | ||
Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection | Q33476165 | ||
CpG methylation controls reactivation of HIV from latency | Q33495565 | ||
Negative elongation factor is required for the maintenance of proviral latency but does not induce promoter-proximal pausing of RNA polymerase II on the HIV long terminal repeat | Q33602605 | ||
Semen-specific genetic characteristics of human immunodeficiency virus type 1 env. | Q33717839 | ||
An HIV-encoded antisense long noncoding RNA epigenetically regulates viral transcription | Q33724213 | ||
The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1 | Q33725916 | ||
Vaginal myeloid dendritic cells transmit founder HIV-1. | Q33744037 | ||
Epigenetic analysis of HIV-1 proviral genomes from infected individuals: predominance of unmethylated CpG's. | Q33768729 | ||
Benzotriazoles Reactivate Latent HIV-1 through Inactivation of STAT5 SUMOylation. | Q33771155 | ||
Human immunodeficiency virus type 1 populations in blood and semen | Q33782102 | ||
HIV DNA in circulating monocytes as a mechanism to dementia and other HIV complications | Q33805298 | ||
High-throughput Characterization of HIV-1 Reservoir Reactivation Using a Single-Cell-in-Droplet PCR Assay | Q33817708 | ||
Entinostat is a histone deacetylase inhibitor selective for class 1 histone deacetylases and activates HIV production from latently infected primary T cells. | Q33838633 | ||
Decay kinetics of human immunodeficiency virus-specific CD8+ T cells in peripheral blood after initiation of highly active antiretroviral therapy | Q33843388 | ||
Involvement of histone H3 lysine 9 (H3K9) methyltransferase G9a in the maintenance of HIV-1 latency and its reactivation by BIX01294. | Q33883423 | ||
The Human Immunodeficiency Virus 1 ASP RNA promotes viral latency by recruiting the Polycomb Repressor Complex 2 and promoting nucleosome assembly | Q33893725 | ||
Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation. | Q34057748 | ||
Altered viral fitness and drug susceptibility in HIV-1 carrying mutations that confer resistance to nonnucleoside reverse transcriptase and integrase strand transfer inhibitors | Q34059119 | ||
Disulfiram reactivates latent HIV-1 expression through depletion of the phosphatase and tensin homolog | Q34284559 | ||
Evidence that CD32a does not mark the HIV-1 latent reservoir. | Q59076591 | ||
Posttranscriptional Regulation of HIV-1 Gene Expression during Replication and Reactivation from Latency by Nuclear Matrix Protein MATR3 | Q59132651 | ||
Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma | Q59151109 | ||
Estrogen receptor-1 is a key regulator of HIV-1 latency that imparts gender-specific restrictions on the latent reservoir | Q59355676 | ||
HIV-1 latent reservoir size and diversity are stable following brief treatment interruption | Q59358567 | ||
Gut and blood differ in constitutive blocks to HIV transcription, suggesting tissue-specific differences in the mechanisms that govern HIV latency | Q59805107 | ||
Procyanidin trimer C1 reactivates latent HIV as a triple combination therapy with kansui and JQ1 | Q59811612 | ||
HIV-1 infection increases microRNAs that inhibit Dicer1, HRB and HIV-EP2, thereby reducing viral replication | Q61809755 | ||
Insight in HIV Integration Site Selection Provides a Block-and-Lock Strategy for a Functional Cure of HIV Infection | Q61813266 | ||
Characterization of the HIV-1 transcription profile after romidepsin administration in ART-suppressed individuals | Q63727608 | ||
Characterization of Intact Proviruses in Blood and Lymph Node from HIV-Infected Individuals Undergoing Analytical Treatment Interruption | Q63728944 | ||
Single-cell characterization and quantification of translation-competent viral reservoirs in treated and untreated HIV infection | Q64097650 | ||
Persistent Viral Reservoirs in Lymphoid Tissues in SIV-Infected Rhesus Macaques of Chinese-Origin on Suppressive Antiretroviral Therapy | Q64253365 | ||
Nephropathy and establishment of a renal reservoir of HIV type 1 during primary infection | Q74111073 | ||
Subcompartmentalization of HIV-1 quasispecies between seminal cells and seminal plasma indicates their origin in distinct genital tissues | Q78678650 | ||
Longitudinal and cross-sectional studies of HIV-1 RNA and DNA loads in blood and the female genital tract | Q80997535 | ||
Lower genitourinary tract sources of seminal HIV | Q83230103 | ||
Histone methyltransferase inhibitors induce HIV-1 recovery in resting CD4(+) T cells from HIV-1-infected HAART-treated patients | Q84066778 | ||
Persistent HIV RNA shedding in semen despite effective antiretroviral therapy | Q84473924 | ||
Using Barcoded HIV Ensembles (B-HIVE) for Single Provirus Transcriptomics | Q88931790 | ||
Variation in cell-associated unspliced HIV RNA on antiretroviral therapy is associated with the circadian regulator brain-and-muscle-ARNT-like-1 | Q90035728 | ||
HIV-1 Vpr mediates the depletion of the cellular repressor CTIP2 to counteract viral gene silencing | Q90069375 | ||
Differentiation into an Effector Memory Phenotype Potentiates HIV-1 Latency Reversal in CD4+ T Cells | Q90440611 | ||
Infrequent HIV Infection of Circulating Monocytes during Antiretroviral Therapy | Q90616753 | ||
The Quest for Cellular Markers of HIV Reservoirs: Any Color You Like | Q90733079 | ||
Hematopoietic Stem and Progenitor Cells Are a Distinct HIV Reservoir that Contributes to Persistent Viremia in Suppressed Patients | Q90776929 | ||
Resident memory T cells are a cellular reservoir for HIV in the cervical mucosa | Q90811783 | ||
Apobec3A maintains HIV-1 latency through recruitment of epigenetic silencing machinery to the long terminal repeat | Q91168113 | ||
Fimepinostat, a novel dual inhibitor of HDAC and PI3K, effectively reverses HIV-1 latency ex vivo without T cell activation | Q91176634 | ||
Microglial Cells: The Main HIV-1 Reservoir in the Brain | Q91219472 | ||
Intact HIV-1 proviruses accumulate at distinct chromosomal positions during prolonged antiretroviral therapy | Q91247946 | ||
A quantitative approach for measuring the reservoir of latent HIV-1 proviruses | Q91284113 | ||
HIV-1 reservoirs in urethral macrophages of patients under suppressive antiretroviral therapy | Q91341307 | ||
Naive CD4+ T Cells Harbor a Large Inducible Reservoir of Latent, Replication-competent Human Immunodeficiency Virus Type 1 | Q91501278 | ||
Resistance to the Tat Inhibitor Didehydro-Cortistatin A Is Mediated by Heightened Basal HIV-1 Transcription | Q91563978 | ||
Heterogeneous HIV-1 Reactivation Patterns of Disulfiram and Combined Disulfiram+Romidepsin Treatments | Q91618889 | ||
Premature aging of T cells is associated with faster HIV-1 disease progression | Q37399302 | ||
Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study | Q37413059 | ||
Development of an Attenuated Tat Protein as a Highly-effective Agent to Specifically Activate HIV-1 Latency | Q37419972 | ||
The integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1. | Q37428017 | ||
Characterization of Cdk9 T-loop phosphorylation in resting and activated CD4(+) T lymphocytes. | Q37429329 | ||
HIV persists in CCR6+CD4+ T cells from colon and blood during antiretroviral therapy | Q37461290 | ||
Promoter Targeting shRNA Suppresses HIV-1 Infection In vivo Through Transcriptional Gene Silencing | Q37489352 | ||
The kidney as a reservoir for HIV-1 after renal transplantation | Q37524140 | ||
Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues | Q37587740 | ||
A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy | Q37604524 | ||
Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies | Q37644561 | ||
HIV-1 persistence in CD4+ T cells with stem cell-like properties | Q37646541 | ||
Multiple Histone Lysine Methyltransferases Are Required for the Establishment and Maintenance of HIV-1 Latency | Q37695602 | ||
Molecular mechanisms of neuroinvasion by monocytes-macrophages in HIV-1 infection | Q37726311 | ||
HMGA1 recruits CTIP2-repressed P-TEFb to the HIV-1 and cellular target promoters | Q37734357 | ||
The lungs as anatomical reservoirs of HIV infection | Q38154849 | ||
HIV-1 latency in monocytes/macrophages | Q38206643 | ||
Characterization of the HIV-1 RNA associated proteome identifies Matrin 3 as a nuclear cofactor of Rev function | Q38257666 | ||
Landscape review of current HIV 'kick and kill' cure research - some kicking, not enough killing. | Q38636019 | ||
CD4 is expressed on a heterogeneous subset of hematopoietic progenitors, which persistently harbor CXCR4 and CCR5-tropic HIV proviral genomes in vivo. | Q38667923 | ||
Promising Role of Toll-Like Receptor 8 Agonist in Concert with Prostratin for Activation of Silent HIV. | Q38727211 | ||
Hyperactivation of HUSH complex function by Charcot-Marie-Tooth disease mutation in MORC2. | Q38743878 | ||
A Novel Histone Deacetylase Inhibitor, AR-42, Reactivates HIV-1 from Chronically and Latently Infected CD4+ T-cells | Q38795594 | ||
HIV-1 transcriptional silencing caused by TRIM22 inhibition of Sp1 binding to the viral promoter | Q38810619 | ||
Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial | Q38958099 | ||
Toll-Like Receptor 7 Agonist GS-9620 Induces HIV Expression and HIV-Specific Immunity in Cells from HIV-Infected Individuals on Suppressive Antiretroviral Therapy | Q38971085 | ||
Short communication: SAHA (vorinostat) induces CDK9 Thr-186 (T-loop) phosphorylation in resting CD4+ T cells: implications for reactivation of latent HIV. | Q39023875 | ||
Position effects influence HIV latency reversal | Q39167914 | ||
Involvement of histone methyltransferase GLP in HIV-1 latency through catalysis of H3K9 dimethylation | Q39173734 | ||
Reactivation capacity by latency-reversing agents ex vivo correlates with the size of the HIV-1 reservoir | Q39276828 | ||
Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B/2A trial | Q39361321 | ||
Transcription regulation through promoter-proximal pausing of RNA polymerase II. | Q39442921 | ||
TLR8 activates HIV from latently infected cells of myeloid-monocytic origin directly via the MAPK pathway and from latently infected CD4+ T cells indirectly via TNF-α. | Q39585002 | ||
Transcriptional interference perturbs the binding of Sp1 to the HIV-1 promoter. | Q39723092 | ||
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy | Q34290545 | ||
Synergistic activation of human immunodeficiency virus type 1 promoter activity by NF-kappaB and inhibitors of deacetylases: potential perspectives for the development of therapeutic strategies | Q34349201 | ||
Triptolide inhibits human immunodeficiency virus type 1 replication by promoting proteasomal degradation of Tat protein | Q34381967 | ||
CD4+ and CD8+ T cell activation are associated with HIV DNA in resting CD4+ T cells | Q34395160 | ||
Transcriptional interference antagonizes proviral gene expression to promote HIV latency | Q34443670 | ||
Nuclear architecture dictates HIV-1 integration site selection. | Q34465264 | ||
A cytoplasmic RNA virus generates functional viral small RNAs and regulates viral IRES activity in mammalian cells | Q34489762 | ||
Persistence of infectious HIV on follicular dendritic cells | Q34512487 | ||
Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy | Q34588169 | ||
Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes | Q34695803 | ||
Healthy HIV-1-infected individuals on highly active antiretroviral therapy harbor HIV-1 in their alveolar macrophages | Q34869340 | ||
HIV DNA reservoir increases risk for cognitive disorders in cART-naïve patients | Q34922069 | ||
HIV-1 Nef sequence and functional compartmentalization in the gut is not due to differential cytotoxic T lymphocyte selective pressure | Q34995124 | ||
Lack of compartmentalization of HIV-1 quasispecies between the gut and peripheral blood compartments | Q35043695 | ||
Peripheral blood CCR4+CCR6+ and CXCR3+CCR6+CD4+ T cells are highly permissive to HIV-1 infection | Q35064033 | ||
Recent observations on HIV type-1 infection in the genital tract of men and women | Q35071029 | ||
The gut mucosal viral reservoir in HIV-infected patients is not the major source of rebound plasma viremia following interruption of highly active antiretroviral therapy | Q35076758 | ||
Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation | Q35077057 | ||
Monocytes mediate HIV neuropathogenesis: mechanisms that contribute to HIV associated neurocognitive disorders | Q35154529 | ||
Dynamics of HIV latency and reactivation in a primary CD4+ T cell model | Q35176166 | ||
Large number of rebounding/founder HIV variants emerge from multifocal infection in lymphatic tissues after treatment interruption | Q35190018 | ||
Epigenetic silencing of HIV-1 by the histone H3 lysine 27 methyltransferase enhancer of Zeste 2. | Q35192959 | ||
Cellular latency in human immunodeficiency virus-infected individuals with high CD4 levels can be detected by the presence of promoter-proximal transcripts | Q35202038 | ||
Compartmentalized replication of R5 T cell-tropic HIV-1 in the central nervous system early in the course of infection | Q35219829 | ||
Human adipose tissue as a reservoir for memory CD4+ T cells and HIV. | Q35318746 | ||
Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations | Q35521811 | ||
HIV envelope-mediated, CCR5/α4β7-dependent killing of CD4-negative γδ T cells which are lost during progression to AIDS | Q35585948 | ||
HIV Latency Is Established Directly and Early in Both Resting and Activated Primary CD4 T Cells. | Q35661660 | ||
Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations. | Q35720063 | ||
Absence of HIV-1 evolution in the gut-associated lymphoid tissue from patients on combination antiviral therapy initiated during primary infection. | Q35729054 | ||
The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo | Q35778783 | ||
Effect of ipilimumab on the HIV reservoir in an HIV-infected individual with metastatic melanoma | Q35822484 | ||
Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. | Q35845347 | ||
Follicular Dendritic Cells Retain Infectious HIV in Cycling Endosomes | Q35856793 | ||
H3K27 Demethylation at the Proviral Promoter Sensitizes Latent HIV to the Effects of Vorinostat in Ex Vivo Cultures of Resting CD4+ T Cells | Q35914266 | ||
Paucity of HIV DNA methylation in latently infected, resting CD4+ T cells from infected individuals receiving antiretroviral therapy | Q35943698 | ||
Longitudinal Genetic Characterization Reveals That Cell Proliferation Maintains a Persistent HIV Type 1 DNA Pool During Effective HIV Therapy | Q35965172 | ||
Human Galectin-9 Is a Potent Mediator of HIV Transcription and Reactivation | Q36037844 | ||
Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients | Q36076018 | ||
CD4+ T Cells Expressing PD-1, TIGIT and LAG-3 Contribute to HIV Persistence during ART. | Q36077348 | ||
Single-Cell Characterization of Viral Translation-Competent Reservoirs in HIV-Infected Individuals | Q36108518 | ||
Screening of an FDA-approved compound library identifies levosimendan as a novel anti-HIV-1 agent that inhibits viral transcription. | Q40070005 | ||
The histone deacetylase inhibitor SAHA simultaneously reactivates HIV-1 from latency and up-regulates NKG2D ligands sensitizing for natural killer cell cytotoxicity | Q40130732 | ||
A Novel Bromodomain Inhibitor Reverses HIV-1 Latency through Specific Binding with BRD4 to Promote Tat and P-TEFb Association. | Q40150438 | ||
Crosstalk between histone modifications indicates that inhibition of arginine methyltransferase CARM1 activity reverses HIV latency. | Q40150928 | ||
Suppression of microRNA-silencing pathway by HIV-1 during virus replication | Q40166750 | ||
Tripartite Motif-Containing Protein 22 Interacts with Class II Transactivator and Orchestrates Its Recruitment in Nuclear Bodies Containing TRIM19/PML and Cyclin T1. | Q40181655 | ||
Relative efficacy of T cell stimuli as inducers of productive HIV-1 replication in latently infected CD4 lymphocytes from patients on suppressive cART. | Q40192992 | ||
SMYD2-Mediated Histone Methylation Contributes to HIV-1 Latency | Q40205664 | ||
HIV persistence in tissue macrophages of humanized myeloid-only mice during antiretroviral therapy | Q40240401 | ||
Transient HIV-specific T cells increase and inflammation in an HIV-infected patient treated with nivolumab | Q40275173 | ||
CD32a is a marker of a CD4 T-cell HIV reservoir harbouring replication-competent proviruses | Q40290840 | ||
A Novel Toll-Like Receptor 9 Agonist, MGN1703, Enhances HIV-1 Transcription and NK Cell-Mediated Inhibition of HIV-1-Infected Autologous CD4+ T Cells | Q40336664 | ||
Ultrasensitive HIV-1 p24 Assay Detects Single Infected Cells and Differences in Reservoir Induction by Latency Reversal Agents | Q40375858 | ||
Assays for precise quantification of total (including short) and elongated HIV-1 transcripts. | Q40391119 | ||
Exploring the anatomical HIV reservoirs: role of the testicular tissue | Q40484243 | ||
Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression | Q40507650 | ||
HIV Latency-Reversing Agents Have Diverse Effects on Natural Killer Cell Function | Q40515496 | ||
Immune tolerance properties of the testicular tissue as a viral sanctuary site in ART-treated HIV-infected adults | Q40525821 | ||
PD-1(+) and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals | Q40653907 | ||
Resting CD4+ T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes | Q40886843 | ||
Activation of latent human immunodeficiency virus by the histone deacetylase inhibitor panobinostat: a pilot study to assess effects on the central nervous system | Q40889762 | ||
Long-term nonprogressor and elite controller patients who control viremia have a higher percentage of methylation in their HIV-1 proviral promoters than aviremic patients receiving highly active antiretroviral therapy | Q41167388 | ||
GENE SILENCING. Epigenetic silencing by the HUSH complex mediates position-effect variegation in human cells. | Q41529408 | ||
Cells nonproductively infected with HIV-1 exhibit an aberrant pattern of viral RNA expression: a molecular model for latency | Q41730261 | ||
Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. | Q41880147 | ||
Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation | Q41885967 | ||
Sequential Vacc-4x and romidepsin during combination antiretroviral therapy (cART): Immune responses to Vacc-4x regions on p24 and changes in HIV reservoirs. | Q41936227 | ||
Compartmentalization and clonal amplification of HIV-1 variants in the cerebrospinal fluid during primary infection | Q41978842 | ||
Cyclin T1 and CDK9 T-loop phosphorylation are downregulated during establishment of HIV-1 latency in primary resting memory CD4+ T cells. | Q42052356 | ||
Suv39H1 and HP1gamma are responsible for chromatin-mediated HIV-1 transcriptional silencing and post-integration latency | Q42100247 | ||
NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation | Q42128724 | ||
Quasispecies tropism and compartmentalization in gut and peripheral blood during early and chronic phases of HIV-1 infection: possible correlation with immune activation markers | Q42243907 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P921 | main subject | heterogeneity | Q928498 |
P304 | page(s) | 3060 | |
P577 | publication date | 2019-01-01 | |
P1433 | published in | Frontiers in Microbiology | Q27723481 |
P1476 | title | Current Status of Latency Reversing Agents Facing the Heterogeneity of HIV-1 Cellular and Tissue Reservoirs | |
P478 | volume | 10 |